Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
|Articles|October 10, 2005
- Applied Clinical Trials-10-11-2005
- Volume 0
- Issue 0
What non-statistitians need to know about statistics
Stephen Senn, Prof Statistics, Univ of Glasgow, Willi Maurer, Global Head Statistical Methodology, Novartis
Advertisement
Stephen Senn, Prof Statistics, Univ of Glasgow,
Willi Maurer, Global Head Statistical Methodology, Novartis
If you really feel uncomfortable around statistics, Senn and Maurer made this session more understandable and enjoyable. The audience laughed a lot, this is most likely the secret to Prof Senn's success with students. The presenters discussed how statistics or biostatistics has changed in the world of clinical R&D to a position of becoming an integral player in R&D.
Also discussed was the use of Bayesian statistics especially as new tools in analysis methods to support innovative and dynamic trial design. Both speakers discussed how dynamic a tool Bayesian statistics can be, and how effectively it can be used in the conclusion section when making a decision about a drug. Prof Senn's book, Dicing with Death, is a great way to get more expertise on the subject and laugh at the same time.
Articles in this issue
about 21 years ago
ICTI Software Used in Major Government Studyabout 21 years ago
Seen and Heardabout 21 years ago
Successful Development of Vaccinesabout 21 years ago
Pharmacovigilance in the EU and under the Clinical Trials Directiveabout 21 years ago
WelcomeAdvertisement
Related to this article
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
What Needs to Happen Beyond the Clinical Trial Modernization Act
2
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
3
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
4
ACT Brief: Community Research Access, Trustworthy AI Assistants, and Individualized Gene Editing Guidance
5